

11 February 2026

India | Equity Research | Results Update

Aurobindo Pharma

Pharma

Subsidiaries to lead the next leg of growth

Aurobindo's Q3FY26 result was in line with our expectation, led by strong traction in Europe (+11% in constant currency) and ARV (22.5%) business, forex benefit also aided growth and margins. US sales declined 3.4% YoY to USD 420mn in the absence of gRevlimid supplies while OTC and injectable portfolios continued to grow at a strong pace. Aurobindo may complete the USD 250mn acquisition of Lannett in Q1FY27, boosting its FY27 US growth by 7%. While performance in core geographies of US and Europe could be decent, faster utilisation of capacity at PEN-G and China plants, coupled with timely launches of biosimilars and biologic CDMO venture, may fetch margin expansion in next couple of years. Management has reiterated FY26 EBITDA margin guidance of 20–21%. Cut FY27/28E EPS by ~1% to factor in lower US sales. Maintain **BUY** with a revised TP of INR 1,490 based on 13x FY28E EPS.

Q3FY26 performance boosted by currency tailwinds

Aurobindo's Q3FY26 revenue grew 8.4% YoY (4.3% QoQ) to INR 86.5bn (I-Sec: INR 86.5bn) driven by Europe and ARV. Gross margin expanded 129bps YoY (flat QoQ) to 59.7% on softer RM costs and better product mix. EBITDA grew 8.9% YoY (+5.7% QoQ) to INR 17.7bn (I-Sec: INR 17.4bn). Margin expanded 11bps YoY (+26bps QoQ) to 20.5% (I-Sec: 20.1%). Adj. PAT grew 5.8% YoY (+10.3% QoQ) to INR 9.3bn (I-Sec: INR 9.6bn).

EU and ARV businesses led growth; US performance was tepid

US sales dipped 3.4% YoY (+2.2% QoQ) to USD 420mn (I-Sec: USD 425mn). Excluding sales of Revlimid, oral solid portfolio recorded a healthy growth. US business could see a CAGR of 3.5% over FY25–28E. Europe revenue grew a robust 27.4% YoY/9.0% QoQ to INR 27.0bn led by strong growth across key markets. Growth markets revenue declined 0.9% YoY/1.9% QoQ to INR 8.7bn. ARV revenue grew 22.5% YoY/15.7% QoQ to INR 3.8bn. API revenue fell 4.3% YoY/+0.2% QoQ to INR 9.6bn.

Ramp-up in utilization at PEN-G plant on cards

PEN-g plant has reached utilisation of 65–70% and achieved EBITDA breakeven with margins expected to improve from FY27. Production has already touched 9,000–10,000MT, and imposition of minimum import price (MIP) along with external sales from Apr'26 could act as key margin catalysts.

Financial Summary

Y/E March (INR mn)	FY25A	FY26E	FY27E	FY28E
Net Revenue	3,17,237	3,35,638	4,16,250	4,70,503
EBITDA	66,054	68,600	89,655	1,05,105
EBITDA Margin (%)	20.8	20.4	21.5	22.3
Net Profit	35,015	35,737	52,889	65,121
EPS (INR)	60.3	61.5	91.1	112.1
EPS % Chg YoY	6.7	2.1	48.0	23.1
P/E (x)	18.9	18.2	12.3	10.0
EV/EBITDA (x)	9.9	9.0	6.6	5.3
RoCE (%)	10.2	9.4	12.8	14.3
RoE (%)	11.2	10.5	14.1	15.5

Abdulkader Puranwala

abdulkader.puranwala@icicisecurities.com
+91 22 6807 7339

Nisha Shetty

nisha.shetty@icicisecurities.com

Darshil Jain

darshil.jain@icicisecurities.com

Market Data

Market Cap (INR)	653bn
Market Cap (USD)	7,209mn
Bloomberg Code	ARBP IN
Reuters Code	ARBN.BO
52-week Range (INR)	1,279 /994
Free Float (%)	48.0
ADTV-3M (mn) (USD)	14.4

Price Performance (%)	3m	6m	12m
Absolute	(2.7)	7.9	(4.5)
Relative to Sensex	(3.5)	2.3	(13.5)

ESG Score	2024	2025	Change
ESG score	66.3	65.9	(0.4)
Environment	62.4	64.0	1.6
Social	50.0	53.1	3.1
Governance	84.2	79.3	(4.9)

Note - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Earnings Revisions (%)	FY27E	FY28E
Revenue	1.1	0.0
EBITDA	(0.3)	(0.4)
EPS	(0.5)	(0.7)

Previous Reports

30-01-2026: [Company update](#)

07-11-2025: [Q2FY26 results review](#)

Valuation and risks

In the past four years, Aurobindo has incurred capex of INR 115bn primarily towards setting up new manufacturing facilities in China, US and India (for PEN-G, biosimilars and biologics) to support growth across verticals. While the production at PEN-G plant is now scaling up to 9,000-10,000MT, the recent imposition of MIP by the Indian government on imports of PEN-G is a major positive for the company and could help it improve the overall profitability (INR 2.4bn in incentive from the government). Supplies from China plant to European market are set to pickup. While performance in Europe continues to stand out led by robust double-digit growth across key markets, it is on track to achieve the guided EUR 1bn revenue in FY26. In next 1-2 years, most new ventures could start contributing to profitability ensuring margins of over 20%, in our view.

Momentum in Eugia Pharma is expected to lead growth in the near term; management expects the injectable portfolio to grow in double digits in FY27. Management believes the Form 483 observations for Unit 3 of Eugia are not critical and regulatory issues could be resolved in the near term. Besides, in CuraTeQ, the biosimilar portfolio continues to advance with filings for Omalizumab and Denosumab planned by Jul'26, alongside multiple approvals expected over FY27-28. Recent launches across Europe strengthen its global footprint, while potential entry into Brazil and Canada could unlock incremental opportunities. On biologics CDMO front, Aurobindo is investing USD 200-210mn in Theranym (USD 120-130mn already incurred) towards setting up a dedicated facility for Merck. The plant may be inaugurated in Jul'26 and commercial supplies to Merck for the two products could begin in FY28.

The stock currently trades at 12.3x FY27E and 10.0x FY28E earnings, and EV/EBITDA multiples of 6.6x FY27E and 5.3x FY28E. We maintain **BUY** with a lower target price of INR 1,490 (earlier INR 1,500), based on 13x FY28E EPS (earlier 16x FY27E EPS).

Key downside risks: Regulatory hurdles, currency volatility and delay in US launches.

Q3FY26 conference call: Highlights

US oral solids

- The company launched nine products and received approval for seven ANDAs from the USFDA in Q3FY26.
- Excluding sales of gRevlimid in FY25, its oral solids sales in the US were stable. Barring sales of gRevlimid, overall revenue grew 9% YoY; gross profit was up 13% and PAT was up 15%, YoY.
- Demand for core products was healthy and was led by better volumes and new product launches.
- Revenue generation from new manufacturing facility in Dayton (US) will start from FY27.
- Acquisition of Lanett will complete in Q1FY27 and will further strengthen its US biz. Liability arising from settlements will be paid by Lannett and Aurobindo will only pay the agreed deal amount on closure of the deal.
- US OTC biz has picked up in the last three years and is a fast-growing segment within the US portfolio.
- The company has witnessed a mere 1% price erosion in oral solids portfolio.
- On track to launch Pomalidamide in the US in Q4FY26.

Eugia (injectables)

- Injectable sales grew 17% YoY. Management expects double-digit growth in FY27 driven by ramp-up in supplies.
- The recent 11 observations for Unit 3 are procedural observations and the company will respond to the USFDA in 15 days.
- It has filed three products from injectable facility in Vizag and plans to file 10 more in the near term. By CY26 end, it will operationalise all the eight lines at Vizag plant and the benefit could reflect from FY28.

Europe

- Growth in Europe was driven by strong performance across all key markets.
- Key geographies are recording double-digit growth; trajectory to improve as supplies from China plant pick up.
- Management is confident of surpassing its Euro 1bn revenue guidance by the end of FY26.
- Captive manufacturing accounts for 60% of regional sales and the balance from third-party sites.

Biologic CMO

- The company has incurred capex of USD 120-130mn so far under TheraNym Biologics and will further spend USD 80 in next two years.
- Deal with Merck includes supplies of two products from the dedicated plant.

Biosimilars

- Planning to file Omalizumab and Densoumab in EU & US by July'26.
- Ranibizumab is an ocular product which requires a minor surgical procedure, and hence, phase 3 is not waived for this product.

- It has launched Bevqolva in the UK and Dazublys in Lithuania while Trastuzumab was launched in Baltic region.
- Plans to foray in Brazil; regulator ANVISA is scheduled to inspect the plant in May'26 post which it may be able to launch four new products in Brazil.
- It has secured approval for Dyruppeg from Health Canada; three additional product filings are under review with approvals expected in CY26.
- Trastuzumab 600mg sub-cutaneous dose is likely to enter clinical studies in CY26.
- It has a robust pipeline of eight early-stage biosimilar candidates in development with a total addressable market opportunity estimate of >USD 50bn in CY32.
- FY29 to be the inflection year for CuraTeQ backed by ramp-up in key products.

PEN-G project

- Production at the plant has reached 65-70% of capacity. In Jan'26, it touched production of 9,000-10,000MT and is working on yield improvement and ramping-up production in balance fermenters.
- MIP will act as a strategic catalyst and will boost the manufacturing of API. Full MIP benefits with rise in Amoxicillin prices will be visible from Apr'26 along with the start in external sales.
- Plant has achieved EBITDA breakeven and margins are expected to improve further from FY27.
- The company is eligible for PLI incentive of INR 2.40bn on production of 10,000MT.

China plant

- The plant is steadily advancing towards an annual capacity of 2bn units supported by EU approval for 10 products and three local product approvals.
- EBITDA breakeven for this plant is targeted in Q4FY26 and a meaningful contribution to EBITDA will start from FY27.

Guidance

- EBITDA margin for FY26 is likely to be in 20-21% range.

Q3FY26 financials

- ARV business sustained momentum aided by higher volume and new tender wins.
- Growth was driven by strong performance in Europe along with stable US and growth markets.
- Gross margin improvement was led by softer RM prices and business mix.
- Capex stood at USD 79mn.
- It had net cash of USD 251mn as on 31st Dec'25.
- It recorded one-time impact of INR 650mn for new labour code.
- It incurred losses due to ramp up in some businesses and higher R&D costs for CuraTeQ. It will take tax credit once these companies start making profit. Tax rate is higher because it is in ramp-up phase and is likely to reduce to ~25% level ahead.
- Impact of INR depreciation is already reflecting in the performance.

Exhibit 1: Quarter review

Y/E Mar (INR mn)	Q3FY26	Q3FY25	YoY (%)	Q2FY26	QoQ (%)	9MFY26	9MFY25	YoY (%)
Net Sales	86,459	79,785	8.4	82,857	4.3	2,47,997	2,33,416	6.2
Gross Profit	51,647	46,631	10.8	49,468	4.4	1,47,405	1,37,433	7.3
Gross Margins (%)	59.7	58.4	129bps	59.7	3bps	59.4	58.9	56bps
R&D	4,669	4,500	3.8	4,140	12.8	12,479	11,990	4.1
R&D (%)	5.4	5.6	-24bps	5.0	40bps	5.0	5.1	-10bps
EBITDA	17,733	16,278	8.9	16,781	5.7	50,549	48,135	5.0
EBITDA Margins (%)	20.5	20.4	11bps	20.3	26bps	20.4	20.6	-24bps
Other Income	1,541	1,573	(2.0)	1,156	33.3	3,751	4,986	(24.8)
Interest	928	1,185	(21.7)	952	(2.6)	2,858	3,422	(16.5)
Depreciation	4,647	4,185	11.0	4,292	8.3	12,996	12,050	7.9
Exceptional Items	-318	-498	-	50	-	-272	-343	-
PBT	13,385	11,999	11.6	12,759	4.9	38,212	37,312	2.4
Tax	4,287	3,543	21.0	4,278	0.2	12,391	11,505	7.7
Tax Rate (%)	32.0	29.5	250bps	33.5	-150bps	32.4	30.8	159bps
Reported PAT	9,103	8,458	7.6	8,485	7.3	25,835	25,824	0.0
Adjusted PAT	9,319	8,809	5.8	8,451	10.3	25,651	25,587	0.2
NPM (%)	10.8	11.0	-26bps	10.2	58bps	10.3	11.0	-62bps


Source: Company data, I-Sec research

Exhibit 2: Business mix

INR mn	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	% YoY	% QoQ
Formulations	58,170	60,530	62,900	65,100	64,750	66,400	69,720	73,130	69,530	73,250	76,830	10.2	4.9
US	33,040	34,700	37,560	35,880	35,550	35,300	36,710	40,720	34,880	36,380	37,390	1.9	2.8
EU	18,370	17,690	17,280	18,320	19,820	21,050	21,210	21,470	23,380	24,800	27,030	27.4	9.0
ARV	1,900	2,500	1,790	2,380	2,290	1,930	3,070	3,080	3,550	3,250	3,760	22.5	15.7
RoW	4,860	5,640	6,270	8,520	7,090	8,120	8,730	7,860	7,720	8,820	8,650	(0.9)	(1.9)
Active Ingredients	10,330	11,660	10,220	10,190	10,920	11,560	10,060	10,690	9,160	9,610	9,630	(4.3)	0.2
Total	68,500	72,190	73,120	75,290	75,670	77,960	79,780	83,820	78,690	82,860	86,460	8.4	4.3
US (USD mn)	382	409	451	432	426	421	435	470	408	417	420	(3.4)	0.7


Source: Company data, I-Sec research

Exhibit 3: US revenue declined due to lower gRevlimid sales




Source: I-Sec research, Company data


Exhibit 4: US revenue likely to report CAGR of 4.2% over FY25-28E




Source: I-Sec research, Company data

Exhibit 5: EU growth driven by traction across key markets


Source: I-Sec research, Company data

Exhibit 6: EU to grow at ~22% CAGR over FY25–28E


Source: I-Sec research, Company data

Exhibit 7: Growth driven by continued traction in Europe and ARV verticals


Source: I-Sec research, Company data

Exhibit 8: Overall revenue to register ~12% CAGR over FY25–28E


Source: I-Sec research, Company data

Exhibit 9: Gross margin expanded 88bps YoY


Source: I-Sec research, Company data

Exhibit 10: Gross margin likely to be ~60% ahead


Source: I-Sec research, Company data

Exhibit 11: EBITDA margin expanded 16bps YoY


Source: I-Sec research, Company data

Exhibit 12: Expect EBITDA margin to recover driven by healthy US sales and cost curtailment


Source: I-Sec research, Company data

Exhibit 13: R&D expenses rose 1.0% YoY


Source: I-Sec research, Company data

Exhibit 14: R&D expenses to be stable at ~5% of sales ahead

Source: I-Sec research, Company data

Exhibit 15: Adj. PAT grew 4.7% YoY

Source: I-Sec research, Company data


Exhibit 16: Adj. PAT to register CAGR of ~21% over FY25-28E

Source: I-Sec research, Company data

Exhibit 17: Shareholding pattern

%	Jun'25	Sep'25	Dec'25
Promoters	51.8	51.8	51.8
Institutional investors	41.4	39.7	39.4
MFs and others	21.1	19.3	19.5
FIs/Banks	0.0	0.3	0.4
Insurance	5.5	5.9	5.5
FIIIs	14.8	14.2	13.9
Others	6.6	8.5	8.8

Source: Bloomberg, I-Sec research

Exhibit 18: Price chart

Source: Bloomberg, I-Sec research

Financial Summary

Exhibit 19: Profit & Loss

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Net Sales	3,17,237	3,35,638	4,16,250	4,70,503
Operating Expenses	2,51,183	2,67,038	3,26,595	3,65,398
EBITDA	66,054	68,600	89,655	1,05,105
EBITDA Margin (%)	20.8	20.4	21.5	22.3
Depreciation & Amortization	16,494	17,616	18,425	19,157
EBIT	49,560	50,985	71,231	85,948
Interest expenditure	4,572	3,766	3,402	3,038
Other Non-operating Income	6,219	5,371	7,771	10,171
Recurring PBT	50,980	52,862	75,600	93,081
Profit / (Loss) from Associates	(317)	(70)	(77)	(84)
Less: Taxes	15,827	16,894	22,657	27,899
PAT	35,153	35,969	52,943	65,182
Less: Minority Interest	(23)	(23)	(23)	(23)
Extraordinaries (Net)	(227)	272	-	-
Net Income (Reported)	34,859	35,922	52,889	65,121
Net Income (Adjusted)	35,015	35,737	52,889	65,121

Source Company data, I-Sec research

Exhibit 20: Balance sheet

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Total Current Assets	2,71,624	3,10,478	3,72,289	4,37,873
of which cash & cash eqv.	82,355	1,13,201	1,27,638	1,61,338
Total Current Liabilities & Provisions	83,023	93,882	1,15,084	1,29,354
Net Current Assets	1,88,601	2,16,596	2,57,205	3,08,519
Investments	2,517	2,517	2,517	2,517
Net Fixed Assets	1,18,950	1,15,740	1,12,094	1,08,003
ROU Assets	2,944	2,652	2,563	2,463
Capital Work-in-Progress	49,000	49,000	49,000	49,000
Total Intangible Assets	26,048	21,708	17,018	12,052
Other assets	13,770	14,315	16,703	18,310
Deferred Tax Assets	12,930	12,930	12,930	12,930
Total Assets	4,14,826	4,35,528	4,70,118	5,13,894
Liabilities				
Borrowings	79,417	72,417	65,417	58,417
Deferred Tax Liability	3,033	3,033	3,033	3,033
provisions	2,829	2,829	2,829	2,829
other Liabilities	3,078	3,257	4,039	4,565
Equity Share Capital	581	581	581	581
Reserves & Surplus	3,25,952	3,53,499	3,94,329	4,44,602
Total Net Worth	3,26,533	3,54,079	3,94,910	4,45,183
Minority Interest	(64)	(87)	(110)	(133)
Total Liabilities	4,14,826	4,35,528	4,70,118	5,13,894

Source Company data, I-Sec research

Exhibit 21: Cashflow statement

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Operating Cashflow	37,314	54,391	39,126	58,415
Working Capital Changes	19,131	11,197	(2,481)	27,795
Capital Commitments	(29,821)	(9,774)	(10,000)	(10,000)
Free Cashflow	7,494	44,617	29,126	48,415
Other investing cashflow	1,205	-	-	-
Cashflow from Investing Activities	(28,615)	(9,774)	(10,000)	(10,000)
Issue of Share Capital	(5)	-	-	-
Interest Cost	-	-	-	-
Inc (Dec) in Borrowings	16,265	(7,000)	(7,000)	(7,000)
Dividend paid	(7,948)	(8,190)	(12,059)	(14,848)
Others	2,556	1,420	4,369	7,133
Cash flow from Financing Activities	10,868	(13,770)	(14,690)	(14,714)
Chg. in Cash & Bank balance	19,567	30,846	14,437	33,700
Closing cash & balance	82,350	1,13,201	1,27,638	1,61,338

Source Company data, I-Sec research

Exhibit 22: Key ratios

(Year ending March)

	FY25A	FY26E	FY27E	FY28E
Per Share Data (INR)				
Reported EPS	59.5	61.8	91.1	112.1
Adjusted EPS (Diluted)	60.3	61.5	91.1	112.1
Cash EPS	87.9	91.9	122.8	145.1
Dividend per share (DPS)	13.6	14.1	20.8	25.6
Book Value per share (BV)	557.3	609.6	679.9	766.5
Dividend Payout (%)	22.8	22.8	22.8	22.8
Growth (%)				
Net Sales	9.4	5.8	24.0	13.0
EBITDA	13.0	3.9	30.7	17.2
EPS (INR)	6.7	2.1	48.0	23.1
Valuation Ratios (x)				
P/E	18.9	18.2	12.3	10.0
P/CEPS	12.8	12.2	9.2	7.7
P/BV	2.0	1.8	1.7	1.5
EV / EBITDA	9.9	9.0	6.6	5.3
P / Sales	2.1	2.0	1.6	1.4
Dividend Yield (%)	1.2	1.3	1.8	2.3
Operating Ratios				
Gross Profit Margins (%)	58.9	59.4	60.0	60.4
EBITDA Margins (%)	20.8	20.4	21.5	22.3
Effective Tax Rate (%)	31.0	32.0	30.0	30.0
Net Profit Margins (%)	11.0	10.6	12.7	13.8
NWC / Total Assets (%)	-	-	-	-
Net Debt / Equity (x)	0.0	(0.1)	(0.2)	(0.2)
Net Debt / EBITDA (x)	(0.1)	(0.6)	(0.7)	(1.0)
Profitability Ratios				
RoCE (%)	10.2	9.4	12.8	14.3
RoE (%)	11.2	10.5	14.1	15.5
RoC (%)	17.6	18.6	24.5	28.9
Fixed Asset Turnover (x)	2.7	2.9	3.7	4.3
Inventory Turnover Days	127	125	134	129
Receivables Days	69	66	71	68
Payables Days	50	57	61	58

Source Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet_babbar@icicisecuritiesinc.com, Rishi_agrawal@icicisecuritiesinc.com and Kadambari_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise)
BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

ANALYST CERTIFICATION

I/We, Abdulkader Puranwala, MBA; Nisha Shetty, MBA; Darshil Jain, MBA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/ beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions. ([Link](#))

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address : complianceofficer@icicisecurities.com

For any queries or grievances: [Mr. Jeetu Jawrani](#) Email address: headservicequality@icicidirect.com Contact Number: 18601231122
